Sökning: WFRF:(Gaarenstroom K. N.) >
Clinical Use of Can...
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer Updated Guidelines From the European Group on Tumor Markers
-
- Soletormos, Gyorgy (författare)
- Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark.
-
- Duffy, Michael J. (författare)
- St Vincents Univ Hosp, Clin Res Ctr, Dublin 4, Ireland.;Univ Coll Dublin, UCD Sch Med & Med Sci, Conway Inst Bimol & Biomed, Res, Dublin 2, Ireland.
-
- Abu Hassan, Suher Othman (författare)
- Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark.
-
visa fler...
-
- Verheijen, Rene H. M. (författare)
- Univ Med, Ctr Utrecht, Dept Gynecol Oncol, Utrecht, Netherlands.
-
- Tholander, Bengt (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Bast, Robert C., Jr. (författare)
- Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gynecol Med Oncol, Houston, TX 77030 USA.
-
- Gaarenstroom, Katja N. (författare)
- Leiden Univ, Med Ctr, Dept Gynecol, Leiden, Netherlands.
-
- Sturgeon, Catharine M. (författare)
- Royal Infirm Edinburgh NHS Trust, Dept Clin Biochem, Edinburgh, Midlothian, Scotland.
-
- Bonfrer, Johannes M. (författare)
- PUM Netherlands Senior Experts, Senior Expert Clin Labs, Heemstede, Netherlands.
-
- Petersen, Per Hyltoft (författare)
- Univ Bergen, Norwegian Qual Improvement Primary Care Labs NOKL, Sect Gen Practice, Bergen, Norway.
-
- Troonen, Hugo (författare)
- Abbott, Limburg, Germany.
-
- CarloTorre, Gian (författare)
- Ctr Ippocrate, Bogliasco, Italy.
-
- Kulpa, Jan Kanty (författare)
- M Sklodowska Curie Mem Inst, Cracow Div, Ctr Oncol, Dept Clin Biochem, Krakow, Poland.
-
- Tuxen, Malgorzata K. (författare)
- Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark.
-
- Molina, Raphael (författare)
- Hosp Clin Barcelona, Biochem Lab, Barcelona, Spain.
-
visa färre...
-
Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark St Vincents Univ Hosp, Clin Res Ctr, Dublin 4, Ireland.;Univ Coll Dublin, UCD Sch Med & Med Sci, Conway Inst Bimol & Biomed, Res, Dublin 2, Ireland. (creator_code:org_t)
- 2016
- 2016
- Engelska.
-
Ingår i: International Journal of Gynecological Cancer. - 1048-891X .- 1525-1438. ; 26:1, s. 43-51
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective:To present an update of the European Group on Tumor Markers guidelines for serum markers in epithelial varian cancer. Methods: Systematic literature survey from 2008 to 2013. The articles were evaluated by level of evidence and strength of recommendation. Results: Because of its low sensitivity (50-62% for early stage epithelial ovarian cancer) and limited specificity (94-98.5%), cancer antigen (CA) 125 (CA125) is not recommended as a screening test in asymptomatic women. The Risk of Malignancy Index, which includes CA125, transvaginal ultrasound, and menopausal status, is recommended for the differential diagnosis of a pelvic mass. Because human epididymis protein 4 has been reported to have superior specificity to CA125, especially in premenopausal women, it may be considered either alone or as part of the risk of ovarian malignancy algorithm, in the differential diagnosis of pelvic masses, especially in such women. CA125 should be used to monitor response to first-line chemotherapy using the previously published criteria of the Gynecological Cancer Intergroup, that is, at least a 50% reduction of a pretreatment sample of 70 kU/L or greater. The value of CA125 in posttherapy surveillance is less clear. Although a prospective randomized trial concluded that early administration of chemotherapy based on increasing CA125 levels had no effect on survival, European Group on Tumor Markers state that monitoring with CA125 in this situation should occur, especially if the patient is a candidate for secondary cytoreductive surgery. Conclusions: At present, CA125 remains the most important biomarker for epithelial ovarian cancer, excluding tumors of mucinous origin.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)
Nyckelord
- Ovarian cancer
- CA125
- HE4
- Screening
- Differential diagnosis
- Monitoring
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Soletormos, Gyor ...
-
Duffy, Michael J ...
-
Abu Hassan, Suhe ...
-
Verheijen, Rene ...
-
Tholander, Bengt
-
Bast, Robert C., ...
-
visa fler...
-
Gaarenstroom, Ka ...
-
Sturgeon, Cathar ...
-
Bonfrer, Johanne ...
-
Petersen, Per Hy ...
-
Troonen, Hugo
-
CarloTorre, Gian
-
Kulpa, Jan Kanty
-
Tuxen, Malgorzat ...
-
Molina, Raphael
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Reproduktionsmed ...
- Artiklar i publikationen
-
International Jo ...
- Av lärosätet
-
Uppsala universitet